Suppr超能文献

关于 COVID-19 mRNA 疫苗的简要综述。

Brief review of the mRNA vaccines COVID-19.

机构信息

Clinical Pharmacologist, Pharmaceutical Department, Usl Umbria 1, A.Migliorati Street, 06132, Perugia, Italy.

Hospital Pharmacist Manager, Pharmaceutical Department, Usl Umbria 1, A.Migliorati Street, 06132, Perugia, Italy.

出版信息

Inflammopharmacology. 2021 Jun;29(3):645-649. doi: 10.1007/s10787-021-00811-0. Epub 2021 May 1.

Abstract

The global COVID-19 pandemic continues to claim victims worldwide, representing a health and socioeconomic challenge with few precedents in human history. The therapeutic agents used to treat COVID-19 infection are mostly aimed at avoiding the most serious complications and organ damage that in a percentage of cases can be fatal. Recently, the first COVID-19 vaccines have been authorised, starting a massive vaccination campaign worldwide. The COVID-19 vaccines authorized or under testing use different methods of action such as mRNA, DNA vaccine, viral vector, protein subunit, and virus inactivated immunization strategies. The mRNA vaccines are the first authorised vaccines with this new method of action, initiating a new era of preventive medicine. To date, data indicate that they may be effective against the newly identified SARS-CoV-2 variants. Short-term studies indicated an acceptable safety profile but long-term immunity as well as safety is not yet available. In this article, we briefly describe mRNA vaccines and highlight some aspects yet to be fully defined.

摘要

全球 COVID-19 大流行仍在全球范围内造成人员伤亡,这是人类历史上前所未有的健康和社会经济挑战。用于治疗 COVID-19 感染的治疗药物主要旨在避免最严重的并发症和器官损伤,在某些情况下,这些并发症和器官损伤可能是致命的。最近,第一批 COVID-19 疫苗已获得授权,全球范围内开始了大规模的疫苗接种运动。已授权或正在测试的 COVID-19 疫苗使用不同的作用方式,如 mRNA、DNA 疫苗、病毒载体、蛋白亚单位和病毒灭活免疫策略。mRNA 疫苗是首批采用这种新作用方式的授权疫苗,开创了预防医学的新纪元。迄今为止,数据表明它们可能对新发现的 SARS-CoV-2 变体有效。短期研究表明安全性良好,但长期免疫和安全性尚不清楚。在本文中,我们简要描述了 mRNA 疫苗,并强调了一些尚未完全确定的方面。

相似文献

1
Brief review of the mRNA vaccines COVID-19.关于 COVID-19 mRNA 疫苗的简要综述。
Inflammopharmacology. 2021 Jun;29(3):645-649. doi: 10.1007/s10787-021-00811-0. Epub 2021 May 1.
3
COVID-19 mRNA vaccines.COVID-19 mRNA 疫苗。
J Genet Genomics. 2021 Feb 20;48(2):107-114. doi: 10.1016/j.jgg.2021.02.006. Epub 2021 Mar 15.
4
SARS-CoV-2 vaccine candidates in rapid development.正在快速开发的 SARS-CoV-2 疫苗候选物。
Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29.
6
SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.SARS-CoV-2 疫苗:成就斐然,仍有许多需要学习。
Ann Intern Med. 2021 May;174(5):687-690. doi: 10.7326/M21-0111. Epub 2021 Jan 19.

引用本文的文献

8
Omicron variant evolution on vaccines and monoclonal antibodies.奥密克戎变异株对疫苗和单克隆抗体的影响。
Inflammopharmacology. 2023 Aug;31(4):1779-1788. doi: 10.1007/s10787-023-01253-6. Epub 2023 May 19.

本文引用的文献

3
Acute Allergic Reactions to mRNA COVID-19 Vaccines.mRNA COVID-19 疫苗的急性过敏反应。
JAMA. 2021 Apr 20;325(15):1562-1565. doi: 10.1001/jama.2021.3976.
5
Drugs acting on the renin-angiotensin system and SARS-CoV-2.作用于肾素-血管紧张素系统的药物与 SARS-CoV-2。
Drug Discov Today. 2021 Apr;26(4):870-874. doi: 10.1016/j.drudis.2021.01.010. Epub 2021 Jan 21.
7
Efficacy of synthetic glucocorticoids in COVID-19 endothelites.合成糖皮质激素在新型冠状病毒肺炎内皮病变中的疗效
Naunyn Schmiedebergs Arch Pharmacol. 2021 May;394(5):1003-1007. doi: 10.1007/s00210-021-02049-7. Epub 2021 Jan 14.
10
Viral targets for vaccines against COVID-19.针对 COVID-19 的疫苗的病毒靶点。
Nat Rev Immunol. 2021 Feb;21(2):73-82. doi: 10.1038/s41577-020-00480-0. Epub 2020 Dec 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验